Merck (NYSE: MRK) reported second quarter 2023 earnings results today. Total worldwide sales were $15 billion, up 3% from the same period a year ago. GAAP net loss was $5.9 billion, or $2.35 per share, compared to net income of $3.9 billion, or $1.55 per share, last year. Adjusted loss per share was $2.06. For […]
Merck (NYSE: MRK) reported second quarter 2023 earnings results today. Total worldwide sales were $15 billion, up 3% from the same period a year ago. GAAP net loss was $5.9 billion, or $2.35 per share, compared to net income of $3.9 billion, or $1.55 per share, last year. Adjusted loss per share was $2.06. For […]
Merck (NYSE: MRK) reported second quarter 2023 earnings results today.
Total worldwide sales were $15 billion, up 3% from the same period a year ago.
GAAP net loss was $5.9 billion, or $2.35 per share, compared to net income of $3.9 billion, or $1.55 per share, last year. Adjusted loss per share was $2.06.
For the full year of 2023, the company expects sales of $58.6-59.6 billion and adjusted EPS of $2.95-3.05.
